Piper Sandler analyst Matt O’Brien downgraded Penumbra (PEN) to Neutral from Overweight with a price target of $374, up from $330, after Boston Scientific (BSX) announced an agreement to acquire the company in a cash and stock transaction that values Penumbra at $374 per share.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PEN:
- Morning Movers: Morgan Stanley and Goldman Sachs lower following Q4 results
- Video: TSMC outlook gives boost to AI trade
- Penumbra Announces Strong Preliminary Revenue Growth for 2025
- Penumbra up 11% to $348 after Boston Scientific buyout offer
- Penumbra sees FY25 revenue $1.401B-$1.403B, consensus $1.38B